1-2 of 2
Tim Mosmann
Close
Save search
Sort by
Journal Articles

Combination Immunotherapy with a CpG Oligonucleotide and Rituximab (R) Augments the Immunological Response and Favorably Alters the Malignant Microenvironment of Follicular Lymphoma (FL).

Free
Jonathan W. Friedberg, MD, MMSc, Jennifer Kelly, MPH, Jeffrey L. Kutok, MD, Rabih Salloum, MD, David C. Fisher, MD, Elizabeth Ronan, Virginia Dalton, RN, Lynn Rich, RN, Diana Marquis, Paul G. Rothberg, MD, Jane Liesveld, MD, Richard I. Fisher, MD, Robert Coffman, PhD, Tim Mosmann, PhD, Arnold S. Freedman, MD
Journal: Blood
Blood (2006) 108 (11): 2713.
https://doi.org/10.1182/blood.V108.11.2713.2713
Published: 2006
Journal Articles

CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment.

Free
Jonathan W. Friedberg, MD, Jennifer Kelly, Jeffrey L. Kutok, MD, Rabih Salloum, MD, Thomas Brenn, MD, David C. Fisher, MD, Elizabeth Ronan, Mary McCauley, RN, Lynn Rich, RN, Diana Marquis, Paul G. Rothberg, PhD, Jane Liesveld, MD, Richard I. Fisher, MD, Robert Coffman, PhD, Tim Mosmann, PhD, Arnold S. Freedman, MD
Journal: Blood
Blood (2005) 106 (11): 2434.
https://doi.org/10.1182/blood.V106.11.2434.2434
Published: 2005